Galapagos NV (XAMS:GLPG) Total Stockholders Equity : €2,747.9 Mil (As of Mar. 2025)

View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Total Stockholders Equity?

Galapagos NV's Total Stockholders Equity for the quarter that ended in Mar. 2025 was €2,747.9 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Galapagos NV's Book Value per Share for the quarter that ended in Mar. 2025 was €41.70. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Galapagos NV's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.00.

Galapagos NV Total Stockholders Equity Historical Data

The historical data trend for Galapagos NV's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Total Stockholders Equity Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

2,670.36

2,643.36

2,526.03

2,795.57

2,896.94

Galapagos NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															2,895.01	2,910.30	2,862.57	2,896.94	2,747.89

Galapagos NV (XAMS:GLPG) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Galapagos NV's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(2747.894	-	0)	/	65.897
	=	41.70

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Galapagos NV's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.071	+	7.787)	/	2747.894
	=	0.00

Galapagos NV Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (XAMS:GLPG) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:USA GLPGa:UK 0JXZ:UK GXEA:Germany GXE:Germany GXEA:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.